|
スズキ ケイタ
Keita Suzuki
鈴木 啓太 所属 川崎医療福祉大学 リハビリテーション学部 理学療法学科 職種 助教 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 表題 | Cystatin C-based eGFR predicts cardiovascular disease in patients with overweight/obesity and hyperglycemia. |
| 掲載誌名 | 正式名：Obesity science & practice 略 称：Obes Sci Pract ISSNコード：20552238/20552238 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 9(1),pp.4-14 |
| 著者・共著者 | Keita Suzuki, Hiromasa Tsujiguchi, Akinori Hara, Hiroyuki Nakamura, Kazuhiko Kotani, Mitsuhiko Noda, Hajime Yamakage, Noriko Satoh-Asahara, Toshinari Takamura |
| 担当区分 | 筆頭著者 |
| 発行年月 | 2023/02 |
| 概要 | BACKGROUND:Although many clinical parameters have been identified as predictors for cardiovascular disease (CVD) development in the general population, the accurate predictor for CVD in patients with obesity is still unknown.OBJECTIVE:The study aimed to explore an additional risk factor and predictor for CVD in patients with overweight/obesity considering the interaction of obesity-related pathophysiology.METHODS:The Japan Obesity and Metabolic Syndrome study, a multicenter prospective study, enrolled 787 outpatients, of which 318 eligible patients were analyzed. Patients with fasting plasma glucose (FPG) levels ≥6.11 and < 6.11 mmol/L were considered to have high FPG (HFPG) and normal FPG (NFPG), respectively. Thirty-six patients who developed CVD during the 5 years follow-up were assigned to the CVD group.RESULTS:Cox's proportional hazards model revealed no significant association between CVD and cystatin C-based estimated glomerular filtration rate (eGFRcys) or creatinine-based eGFR (eGFRcr) in the NFPG group. In the HFPG group, lower eGFRcys, but not eGFRcr, was significantly associated with CVD development. A generalized linear mixed model demonstrated greater reduction in eGFRcys levels over time with HFPG than with NFPG. Although the CVD group showed gradual reduction in eGFRcys levels, the non-CVD group-matched using propensity scores-did not show a decline in eGFRcys levels.CONCLUSIONS:Lower eGFRcys levels may be more accurate than eGFRcr in predicting CVD development in patients with overweight/obesity and hyperglycemia. Furthermore, eGFRcys reduction over time is associated with CVD development.CLINICAL TRIAL REGISTRY NUMBER:UMIN000000559. |
| DOI | 10.1002/osp4.630 |
| PMID | 36789028 |